OTR Therapeutics Deal History & Licensing Activity
OTR Therapeutics is a biotech. Over the past three years, OTR Therapeutics has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Other
Focus Area
Oncology
OTR Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving OTR Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | LG Chem | Other | Discovery | collaboration | Jul 7, 2026 |
| Undisclosed | Zealand Pharma | Small Molecules | Discovery | collaboration | Dec 11, 2025 |
OTR Therapeutics Pipeline Focus
Therapeutic areas and modalities where OTR Therapeutics is most active based on deal history and clinical trial data.
Modalities
See How Your Asset Matches OTR Therapeutics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About OTR Therapeutics Licensing & Deal Activity
OTR Therapeutics is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, OTR Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for OTR Therapeutics include Oncology (2 deals and trials), and Metabolic (2 deals and trials). In terms of modality, OTR Therapeutics has shown particular interest in other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for OTR Therapeutics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against OTR Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.